Sera Prognostics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Sera Prognostics said 3rd quarter 2026 test volume increased 54% sequentially and approximately 5-fold compared with the 1st quarter of 2026; the number of physicians ordering Preterm nearly tripled compared with the 1st quarter.
- The company reported Medicaid coverage for Preterm in Illinois and Florida, representing approximately 7 million covered lives and approximately 140,000 Medicaid births per year.
- In Illinois, Sera onboarded 9 providers and 8 accounts in 2 months, conducted over 100 field activities across 60 practices, and reached over 70 providers in the first month.
- Sera reported 48 medical education meetings and 24 implementation meetings during the quarter, and said Preterm.com traffic increased dramatically.
- ASPs declined in the 3rd quarter as a larger percentage of patients came from low or non-reimbursed patient classes.
- Total operating expenses declined 11% sequentially, partly offset by incremental commercial investments in Illinois and Florida; Sera ended the quarter with $72.8 million in cash and cash equivalents.
- Sera recognized its first milestone payment under a subcontract award for contract research services as other income.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, ladies and gentlemen, and welcome to the Sera Prognostics Third Quarter 2026 Financial Results. At this time, all lines in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for a question. If anyone has any difficulties hearing the conference, please press star 0 for operator assistance at any time. I would like to remind everyone that this call is being recorded on Wednesday, November 4, 2026. I would now like to turn the call over to Jennifer Zibuda, Head of Investor Relations.
Please go ahead. Thank you, operator.
Welcome to Sera Prognostics Third Quarter 2026 Earnings Conference Call. Earlier today, Sera reported financial results for the quarter which ended September 30, 2026. Joining me on today's call are Zhenya Lindgardt, President and Chief Executive Officer, Lee Anderson, Chief Commercial Officer, Tiffany Inglis, Chief Medical Officer, and Scott Gleason, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. A copy of today's earning release can be found on the investor section of our website at sera.com, and a replay of this webcast will also be available. We have also posted an accompanying slide deck presentation pertaining to today's earnings call on the events section of our Investor Relations website.
Before we begin, please note that today's discussion will include projections or forward-looking statements about events and circumstances that have not yet occurred, including regarding our business, future financial results and performance, and market opportunities. These statements are based on our current expectations and are subject to risk factors and uncertainties that could cause actual results to differ materially and adversely from these expectations and forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent forms 10-K, 10-Q, and eight-K for important information regarding these risk factors. With that, I will turn the call over to Zhenya.
Good afternoon, everyone, and thank you for joining us today. At Sera, we believe we are building something truly unique in healthcare. We have developed one of the most highly validated advanced lab tests in history, addressing one of the most important and underserved challenges in medicine, preterm birth. The PreTRM test has demonstrated the ability to identify high-risk pregnancies early and drive meaningful improvements in outcomes for mothers and babies. We are no longer simply an evidence generation story. We are actively transitioning into the commercialization phase of our journey with the goal of establishing PreTRM as a foundational component of prenatal care. The opportunity remains largely untapped, with no effective standard for broad population screening of preterm birth risk.
As a result, we believe there is the potential to create a new category in prenatal care and address one of the largest unmet needs in healthcare while driving substantial long-term value for shareholders. The third quarter represented a significant step forward in that journey. Following publication of the landmark PRIME study and the addition of highly experienced commercial leaders to our management team, we saw strong momentum in the third quarter. Compared to the first quarter of this year, the number of physicians ordering PreTRM nearly tripled. Test volume increased approximately fivefold. We believe these results provide early evidence that the combination of compelling clinical data and focused commercial execution can drive meaningful adoption of PreTRM in real-world clinical practice. We also continue to make significant progress on reimbursement as we execute a multi-tiered strategy to expand coverage across both state Medicaid programs and commercial insurers.
We now have seen a second major Medicaid state cover the test. Florida has established coverage for Medicaid beneficiaries and has added the PreTRM test as a covered service under the state biomarker testing law. Additionally, pricing has been established on the state's fee schedule. With nearly 90,000 Medicaid births and approximately 4 million Medicaid lives, Florida represents our largest reimbursed market opportunity to date. More importantly, we believe Florida further validates a repeatable pathway for expansion into additional states in a market where Medicaid policy often serves as a catalyst for broader adoption. Combined with coverage in Illinois, these milestones demonstrate the growing recognition of the clinical and economic burden of PreTRM birth and the need for solutions that improve outcomes while also reducing healthcare costs.
Supported by strong clinical utility data, compelling health economic evidence, increasing provider engagement, and growing public policy focus on maternal health, we believe we're well-positioned to accelerate adoption of PreTRM and advance our long-term vision of establishing the test as a standard component of prenatal care. While our immediate focus remains on executing in the U.S., our long-term vision is to build a truly global company. As evidence of our progress, we continue to advance our international strategy and remain on track to pursue CE Mark approval for PreTRM Global, our kit-based version of PreTRM, in 2027. In parallel, we are engaged in active discussions with potential commercial partners, including both laboratory and in vitro diagnostic companies, as we evaluate opportunities to expand access to PreTRM in markets outside the U.S.
We have successfully completed our registration study and are working with our notified body on our CE Mark submission. This represents an important milestone in our growth strategy. The addressable market opportunity outside the U.S. is at least as large as our domestic market. We believe these efforts have the potential to establish a meaningful new growth engine and further advance our mission of improving outcomes for mothers and babies around the world. As we go forward, we're actively focused on executing on three critical strategic imperatives to achieving our long-term goals. These include, first, demonstrating a repeatable and scalable commercial model. Our priority is to validate and scale our commercial model in reimbursed markets. With coverage now established in Illinois and Florida, we have two significant opportunities to demonstrate how strong clinical evidence, reimbursement, and focused field execution can drive adoption.
We believe success in these markets will not only support near-term growth, but also establish a playbook for expansion into additional geographies and validate the scalability of our commercial strategy. Next, converting leading clinical evidence into expanding reimbursement and market access. Our second priority is to convert our best-in-class evidence base into broader reimbursement coverage and increase adoption of PreTRM. We are executing a comprehensive market access strategy designed to expand coverage across both Medicaid and commercial payer channels while establishing the foundation for long-term growth. We believe the growing national focus on maternal health creates a favorable environment for additional state Medicaid coverage mandates in 2027 and beyond. We are actively supporting professional guideline inclusion based on the strong clinical utility and health economic outcomes demonstrated through PRIME.
We are also evaluating opportunities to take advantage of existing legislative actions and laws supporting improved maternal and neonatal care, which will collectively impact nearly 1.4 million births each year. We believe these efforts position us to expand access to PreTRM, strengthen reimbursement, and move closer to our goal of making PreTRM birth risk assessment a routine component of prenatal care. Finally, driving capital-efficient growth. Our third priority is to maintain a disciplined approach to capital allocation and ensure that every dollar we invest is directed towards our highest return opportunities. As part of our 2027 planning process, we are carefully evaluating our cost structure, identifying opportunities to improve efficiency and streamline operations, and reallocating resources towards initiatives that directly support commercial growth and market expansion.
Our goal is to maximize return on invested capital while building the capabilities, infrastructure, and market presence necessary to support the next stage of our growth. To provide more detail on our progress against these strategic priorities, I will now turn the call over to our Chief Commercial Officer, Lee Anderson, to discuss our commercial execution.
Lee? Thank you, Zhenya. We saw a significant positive inflection in the third quarter with new ordering accounts, new ordering providers, and total ordering providers outperforming Q2 levels.
This trend delivered a 54% increase in test volume sequentially, demonstrating our commercial model is effectively driving adoption of PreTRM. The third quarter was defined by two important milestones: the approval of Medicaid coverage in Illinois and our commercial expansion in Florida following established Medicaid coverage under the state's biomarker testing law. These two states represent approximately 7 million newly covered lives, encompassing approximately 140,000 Medicaid births per year. Illinois represented our first large-scale state coverage activation effort and will serve as the blueprint for future market launches. In anticipation of coverage becoming effective, we expanded our Illinois field presence in late August with additional regional account executives and a medical science liaison.
The team is focused on high-value provider targets, Medicaid-heavy practices, and clinical key stakeholders. We saw significant interest and engagement from physicians wanting to learn about PreTRM testing. In the first month, we conducted over 100 field activities across 60 practices and reached over 70 providers. In just two months, we have onboarded nine providers and eight accounts, working with them to incorporate PreTRM into their clinical workflow. Some of these providers deliver 500 or more babies per year, creating a significant opportunity to drive adoption of PreTRM. We have focused efforts to support driving practices towards standard of care by changing practice patterns, educating the support staff, and when needed, integrating with electronic medical records to support workflows. Late in the third quarter, we began replicating the Illinois playbook in Florida to maximize the opportunity of state Medicaid coverage.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
